Details of Disease

General Information of Disease (ID: DISUB5FB)

• Disease Name: B-cell non-hodgkin lymphoma
• Synonyms: B-cell NHL; non-Hodgkin's lymphoma B-cell; B-cell non-Hodgkin's lymphoma; B-cell lymphoma; B-cell non-Hodgkin lymphoma; B-cell non Hodgkin's lymphoma; non-Hodgkin's B-cell lymphoma; lymphomas non-Hodgkin's B-cell
• Disease Class: 2B33: Malignant haematopoietic neoplasm
• Definition: The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003
• Disease Hierarchy:
  DISS2Y8A: Non-hodgkin lymphoma
  DISVY326: B-cell neoplasm
  DISUB5FB: B-cell non-hodgkin lymphoma
• ICD Code:
  ICD-11: ICD-11: 2B33.5
  ICD-10: ICD-10: C85.9
  Expand ICD-9: 200202

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ibrutinib	DMHZCPO	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 19 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABP 798	DMSX35S	Phase 3	NA	[2]
Hu5F9-G4	DMBER0Q	Phase 3	NA	[1]
DEBIO 1562	DMCNX02	Phase 2	NA	[1]
LAM-002	DMR0N74	Phase 2	NA	[1]
MT-3724	DMCNL7Z	Phase 2	Recombinant?protein	[1]
Odronextamab	DMP6NVV	Phase 2	Antibody	[3]
REGN1979	DMSJ3Z5	Phase 2	NA	[4]
Urelumab	DM6RTVG	Phase 2	NA	[2]
Anti-CD19-CAR vector-transduced T cells	DMQXU4C	Phase 1/2	CAR T Cell Therapy	[5]
CD19 CAR T cells	DMMHLJQ	Phase 1/2	CAR T Cell Therapy	[6]
GEN3009	DMD8RLY	Phase 1/2	Antibody	[7]
JCAR014	DMTMVEW	Phase 1/2	CAR T Cell Therapy	[1]
JCAR017	DMJV2IF	Phase 1/2	CAR T Cell Therapy	[2]
MB-106	DM9RBUZ	Phase 1/2	NA	[8]
ADCT-402	DMCBIKO	Phase 1	NA	[2]
AFM11	DMIFJZD	Phase 1	Antibody	[2]
CAR-20/19-T Cells	DM4CXE2	Phase 1	CAR T Cell Therapy	[9]
CD19 CAR T cells	DMB8RI6	Phase 1	CAR T Cell Therapy	[10]
TT-01488	DMHTGB5	Phase 1	NA	[11]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IL-18BP	DMRSJ49	Discontinued in Phase 1	NA	[12]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT05685173) A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1). U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT03888105) Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
• [6] ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
• [7] ClinicalTrials.gov (NCT04358458) First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
• [9] ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
• [10] ClinicalTrials.gov (NCT03029338) CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
• [11] ClinicalTrials.gov (NCT05683717) A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies. U.S.National Institutes of Health.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013227)